Related references
Note: Only part of the references are listed.Coronavirus Disease 2019-Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients
Nitipong Permpalung et al.
CLINICAL INFECTIOUS DISEASES (2022)
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study
Prithviraj Bose et al.
CLINICAL INFECTIOUS DISEASES (2021)
Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study
Michele Bartoletti et al.
CLINICAL INFECTIOUS DISEASES (2021)
The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain
Jose Ramon Azanza et al.
MYCOSES (2021)
Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience
Christine A. Vu et al.
TRANSPLANT INFECTIOUS DISEASE (2021)
Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity
Marina Machado et al.
MYCOSES (2021)
Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches
Jeffrey D. Jenks et al.
MYCOSES (2021)
Invasive Fungal Disease Among Pediatric and Adolescent Patients Undergoing Itraconazole Prophylaxis After Hematopoietic Stem Cell Transplantation
Suluk Itsaradisaikul et al.
TRANSPLANTATION PROCEEDINGS (2021)
Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Antonio C. Arrieta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Azole resistance in Aspergillus species: promising therapeutic options
Shirisha Pasula et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
Yael Bogler et al.
MEDICAL MYCOLOGY (2021)
Aspergillosis Complicating Severe Coronavirus Disease
Kieren A. Marr et al.
EMERGING INFECTIOUS DISEASES (2021)
Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients
Lauren Fontana et al.
CLINICAL INFECTIOUS DISEASES (2020)
The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom
Lefteris Floros et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system
Stefan Schwartz et al.
MEDICAL MYCOLOGY (2020)
Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation
Christina Linke et al.
MYCOSES (2020)
A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Anat Stern et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Exploring the molecular mechanism of azole resistance in Aspergillus fumigatus
P. Chen et al.
JOURNAL DE MYCOLOGIE MEDICALE (2020)
Late Onset Invasive Pulmonary Aspergillosis in Lung Transplant Recipients in the Setting of a Targeted Prophylaxis/Preemptive Antifungal Therapy Strategy
Sabina Herrera et al.
TRANSPLANTATION (2020)
Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19
Alexandre Alanio et al.
LANCET RESPIRATORY MEDICINE (2020)
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion
Paul E. Verweij et al.
INTENSIVE CARE MEDICINE (2020)
Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center
Marcela Rubio-Carrasquilla et al.
MEDICAL MYCOLOGY (2020)
Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center
Lionel Lum et al.
TRANSPLANT INFECTIOUS DISEASE (2020)
Colistin and Isavuconazole Interact Synergistically In Vitro against Aspergillus nidulans and Aspergillus niger
Patrick Schwarz et al.
MICROORGANISMS (2020)
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
Philipp Koehler et al.
LANCET INFECTIOUS DISEASES (2020)
Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients
Adam J. DiPippo et al.
MYCOSES (2019)
EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
Karin Meinike Jorgensen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005-2016
Jake C. Valentine et al.
BMC INFECTIOUS DISEASES (2019)
Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy
Adam J. DiPippo et al.
CLINICAL INFECTIOUS DISEASES (2019)
Real-world use-Isavuconazole at a large academic medical center
Habiba Hassouna et al.
MYCOSES (2019)
Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center
Edward T. Van Matre et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2019)
Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre
Christina D. Bowen et al.
MYCOSES (2019)
Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study
Nicola Stefano Fracchiolla et al.
PLOS ONE (2019)
Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation
Gillen Oarbeascoa et al.
CHEMOTHERAPY (2019)
A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation
N. Decembrino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases
Thomas Kaindl et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Prevalence and Outcome of Systemic Fungal Infections in Renal Transplant Recipients - A Tertiary Care Experience
Manikantan Shekar et al.
SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION (2019)
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study
Chiara Cattaneo et al.
HEMASPHERE (2019)
Outbreak of invasive aspergillosis in heart transplant recipients: The role of screening computed tomography scans in asymptomatic patients and universal antifungal prophylaxis
Dima Kabbani et al.
TRANSPLANT INFECTIOUS DISEASE (2018)
Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials
David Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009-2013
Marya D. Zilberberg et al.
CLINICAL INFECTIOUS DISEASES (2018)
Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
Monica Fung et al.
CLINICAL INFECTIOUS DISEASES (2018)
Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
Emma Bagshaw et al.
FUTURE MICROBIOLOGY (2018)
Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study
Ming-Yu Lien et al.
PLOS ONE (2018)
Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
Rachel Harrington et al.
ADVANCES IN THERAPY (2017)
Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects
Takao Yamazaki et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
Robert Townsend et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats
Anne-Hortense Schmitt-Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
Andreas H. Groll et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?
Paul E. Verweij et al.
CLINICAL INFECTIOUS DISEASES (2016)
Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
Vidmantas Petraitis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
Laura L. Kovanda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
Amit Desai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
Thomas F. Patterson et al.
CLINICAL INFECTIOUS DISEASES (2016)
Adverse effects of voriconazole: Over a decade of use
Miriam T. Levine et al.
CLINICAL TRANSPLANTATION (2016)
Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation
Yao-Chung Liu et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2016)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens et al.
LANCET (2016)
Clinical implications of globally emerging azole resistance in Aspergillus fumigatus
Jacques F. Meis et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2016)
Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis
Laura L. Kovanda et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Isavuconazonium: First Global Approval
Paul L. McCormack
DRUGS (2015)
Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009)
Lena Klingspor et al.
MYCOSES (2015)
Invasive Fungal Infections After Kidney Transplantation: A Single-center Experience
T. Santos et al.
TRANSPLANTATION PROCEEDINGS (2015)
A Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically Ill Patients
Stijn I. Blot et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India
Anuradha Chowdhary et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifu.ngal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing
Shivaprakash M. Rudramurthy et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Clinical risk factors for invasive aspergillosis
John W. Baddley
MEDICAL MYCOLOGY (2011)
Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database
Dimitrios P. Kontoyiannis et al.
CLINICAL INFECTIOUS DISEASES (2010)
Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET)
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2010)
In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing
Susanne Perkhofer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species
Jesus Guinea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben De Pauw et al.
CLINICAL INFECTIOUS DISEASES (2008)
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus
Peter A. Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
PA Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Share Paper
